Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stake Decreased by One Capital Management LLC

One Capital Management LLC decreased its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 719,814 shares of the company’s stock after selling 10,129 shares during the period. One Capital Management LLC owned 0.10% of Global X Genomics & Biotechnology ETF worth $6,989,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter worth approximately $50,000. Oxinas Partners Wealth Management LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter worth approximately $103,000. Sanctuary Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter worth approximately $104,000. Atria Investments Inc acquired a new stake in Global X Genomics & Biotechnology ETF in the third quarter worth approximately $122,000. Finally, Smartleaf Asset Management LLC lifted its position in Global X Genomics & Biotechnology ETF by 11.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock worth $122,000 after purchasing an additional 1,265 shares during the period. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

GNOM opened at $9.11 on Thursday. The company has a market capitalization of $63.50 million, a price-to-earnings ratio of -3.89 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 1-year low of $8.64 and a 1-year high of $12.20. The business has a 50 day moving average price of $9.83 and a two-hundred day moving average price of $10.45.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.